Latest News and Press Releases

JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...

JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop,...

JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...

JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding...

JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...

HEIDELBERG, Germany, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target...

Burlingame, Feb. 08, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global recombinant protein market is estimated to be valued at US$ 2,808.4 million in 2022 and is expected to...